Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

British Journal of Haematology

Volumn 161, Issue 3, 2013, Pages 339-347

  Lee, Yun Gyoo ^a   Kim, Inho ^a   Yoon, Sung Soo ^a   Park, Seonyang ^a   Cheong, June Won ^b   Min, Yoo Hong ^b   Lee, Jeong Ok ^c   Bang, Soo Mee ^c   Yi, Hyeon Gyu ^d   Kim, Chul Soo ^d   Park, Yong ^e   Kim, Byung Soo ^e   Mun, Yeung Chul ^f   Seong, Chu Myoung ^f   Park, Jinny ^g   Lee, Jae Hoon ^g   Kim, Sung Yong ^h   Lee, Hong Ghi ^h   Kim, Yeo Kyeoung ⁱ   Kim, Hyeoung Joon ⁱ  

^a Seoul National University Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Ewha Womans University School of Medicine   (South Korea)

^g Gachon University College of Medicine   (South Korea)

^h Konkuk University School of Medicine   (South Korea)

ⁱ Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

Azacitidine; Comparison; Decitabine; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIINFECTIVE AGENT; AZACITIDINE;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; AZACITIDINE; BONE MARROW EXAMINATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFECTION CONTROL; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876168826     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12256     Document Type: Article

References (18)

1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
2. Borthakur, G., Ahdab, S.E., Ravandi, F., Faderl, S., Ferrajoli, A., Newman, B., Issa, J.P. & Kantarjian, H. (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leukaemia & Lymphoma, 49, 690-695.
3. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
4. D'Agostino, R.B. Jr. (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17, 2265-2281.
5. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10, 223-232.
6. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
7. Gurion, R., Vidal, L., Gafter-Gvili, A., Belnik, Y., Yeshurun, M., Raanani, P. & Shpilberg, O. (2010) 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis. Haematologica, 95, 303-310.
8. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y. & Maciejewski, J.P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325.
9. Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R. & Pazdur, R. (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist, 10, 176-182.
10. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, R. 3rd, Shen, L., Nimer, S.D., Leavitt, R., Raza, A. & Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
11. Kumar, A., List, A.F., Hozo, I., Komrokji, R. & Djulbegovic, B. (2010) Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica, 95, 340-342; author reply 343-344.
12. Leuven, E. & Sianesi, B. (2010) PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. WWW document. URL, http://EconPapers.repec.org/RePEc:boc:bocode:s432001
13. Lubbert, M., Suciu, S., Baila, L., Ruter, B.H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H.R., Beeldens, F., Muus, P., Pfluger, K.H., Coens, C., Hagemeijer, A., Eckart Schaefer, H., Ganser, A., Aul, C., de Witte, T. & Wijermans, P.W. (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 1987-1996.
14. Seymour, J.F., Fenaux, P., Silverman, L.R., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., List, A.F., Gore, S.D., Backstrom, J., McKenzie, D. & Beach, C.L. (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology Hematology, 76, 218-227.
15. Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429-2440.
16. Tefferi, A. & Vardiman, J.W. (2009) Myelodysplastic syndromes. New England Journal of Medicine, 361, 1872-1885.
17. Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292-2302.
18. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.